EGFR and non-small cell lung carcinoma: For patients affected by metastatic NSCLC, activating epidermal growth factor receptor (EGFR) mutations occur in almost 10–12% of cases and tyrosine kinase inhibitors (TKIs) are the standard front-line therapy [6].